📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-29 15:22
122 analysed today
FollowTelegram
122
Today
149,523
All-time analysed
42,890
Positive
6,652
Negative
91,308
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
7 announcements match the current filters (relevance ≥ 5).
Lincoln Pharma Sets Sept 11, 2026 as Record Date for ₹1.80/Share (18%) Final Dividend
Lincoln Pharmaceuticals Limited has fixed Friday, September 11, 2026, as the record date for determining shareholder entitlement to a final dividend of ₹1.80 per equity share (18% on face value of ₹10) for FY 2025-26. The payment remains subject to shareholder approval at the company's 32nd Annual General Meeting scheduled for September 30, 2026. At the current market price of ₹615, the dividend translates to a dividend yield of ~0.29%. The share transfer books will remain closed from September 12, 2026, to September 30, 2026.
Confidence: HIGH
What changedLincoln Pharma has formalized the record date and AGM timeline for the distribution of its FY26 final dividend.
Why it mattersDefines the exact cut-off timeline for shareholders to receive the ₹1.80 per share cash distribution from FY26 profits.
Final dividend per share: ₹ 1.80Dividend percentage: 18%Record date: 11-Sep-2026AGM date: 30-Sep-2026Dividend yield at ₹615: ~0.29%
📅 Short termStock will trade ex-dividend leading into the September 11, 2026 record date with negligible price impact given the small yield (~0.29%).
📈 Long termLimited; routine annual capital allocation and dividend distribution.
Key Highlights
Final dividend of ₹1.80 per equity share of face value ₹10 (18%) for FY26
Record date set for Friday, September 11, 2026
Book closure scheduled from September 12, 2026 to September 30, 2026
32nd Annual General Meeting scheduled for Wednesday, September 30, 2026
👀 What to Watch
Investors tracking dividend payouts should note the September 11, 2026 record date and track the outcome of the 32nd AGM on September 30, 2026.
31% YoY PAT Growth in Q1 FY27; Revenue Rises 15% to ₹177.3 Cr
Lincoln Pharmaceuticals reported a strong start to FY27 with a 30.9% YoY increase in Net Profit to ₹36.23 Cr. Revenue from operations grew 15.1% YoY to ₹177.28 Cr, representing approximately 26.4% of its TTM revenue. Profitability was significantly higher than the preceding quarter (Q4 FY26 PAT was ₹11.63 Cr), supported by a recovery in margins. The company maintains a robust financial position with a near-zero debt-to-equity ratio of 0.01.
Confidence: HIGH
What changedLincoln Pharmaceuticals released its Q1 FY27 results, showing a significant recovery in profitability compared to the previous quarter and strong double-digit growth on a YoY basis.
Why it mattersThe results demonstrate the company's ability to scale its formulations business and maintain margins despite a high export exposure (60+ countries). The strong EPS growth supports the current P/E valuation of 13.9x.
Revenue (Q1 FY27): ₹177.28 CrNet Profit (Q1 FY27): ₹36.23 CrYoY PAT Growth: 30.9%Q1 Revenue vs TTM Revenue: 26.4%EPS (Q1 FY27): ₹18.09
📅 Short termThe stock may see positive sentiment in the short term as the market reacts to the 31% YoY profit growth and the sharp sequential recovery from Q4 FY26.
📈 Long termStructural growth depends on the successful entry into high-value regulated markets like Canada, Australia, and the EU, alongside the shift toward high-margin chronic and lifestyle segments.
⚠ Risk flags
- Foreign exchange fluctuations impacting export realizations
- Regulatory risks associated with EU GMP and TGA standards
Key Highlights
Net Profit increased by 30.9% YoY to ₹36.23 Cr from ₹27.68 Cr in Q1 FY26
Revenue from operations grew 15.1% YoY to ₹177.28 Cr
Earnings Per Share (EPS) for the quarter rose to ₹18.09 from ₹13.82 YoY
Profit Before Tax (PBT) stood at ₹47.55 Cr, a 34.4% increase over the ₹35.39 Cr reported in Q1 FY26
Other expenses were reduced to ₹31.40 Cr from ₹40.89 Cr in the preceding quarter
👀 What to Watch
Monitor the commercialization timeline of the Cephalosporin plant and the progress of the 700-product R&D pipeline, which are critical for reaching the management's ₹750 Cr revenue target.
Lincoln Pharma Recommends ₹1.80 Dividend; FY26 Net Profit Rises to ₹87.89 Crore
Lincoln Pharmaceuticals reported a steady performance for the full year ended March 31, 2026, with total income growing 9.1% to ₹704.48 crore. The company's annual net profit increased by 6.7% year-on-year to ₹87.89 crore, resulting in an improved EPS of ₹43.88. A final dividend of ₹1.80 per share (18%) has been recommended for shareholder approval. While annual growth is positive, the Q4 net profit remained relatively flat at ₹11.63 crore compared to the same period last year.
Key Highlights
Recommended a final dividend of ₹1.80 per equity share (18% of face value) for FY26.
Annual Revenue from Operations grew 7.7% year-on-year to ₹671.03 crore.
Full-year Net Profit increased to ₹87.89 crore from ₹82.35 crore in the previous fiscal.
Earnings Per Share (EPS) improved to ₹43.88 from ₹41.11 in FY25.
Cash and cash equivalents increased to ₹21.09 crore as of March 31, 2026, up from ₹12.97 crore.
👀 What to Watch
Investors should consider the steady growth and consistent dividend payout as a sign of financial stability. The stock remains a solid hold for long-term investors given the healthy balance sheet and moderate earnings growth.
Lincoln Pharma FY26 Net Profit Rises 6.7% to ₹87.89 Cr; Recommends ₹1.80 Dividend
Lincoln Pharmaceuticals reported a steady performance for the financial year ended March 31, 2026, with annual revenue growing 7.7% to ₹671.03 crore. Net profit for the full year increased by 6.7% to ₹87.89 crore, up from ₹82.35 crore in the previous fiscal year. The Board has recommended a dividend of ₹1.80 per share (18% of face value), reflecting consistent shareholder returns. While the Q4 net profit of ₹11.63 crore remained relatively flat compared to the same quarter last year, the overall annual EPS improved to ₹43.88.
Key Highlights
Annual Revenue from Operations increased 7.7% YoY to ₹67,102.99 Lakhs.
Full-year Net Profit rose to ₹8,789.38 Lakhs compared to ₹8,234.64 Lakhs in FY25.
Recommended a dividend of ₹1.80 per equity share of face value ₹10.
Annual Earnings Per Share (EPS) improved to ₹43.88 from ₹41.11 in the previous year.
Total Comprehensive Income for the year stood at ₹8,956.88 Lakhs.
👀 What to Watch
The company shows steady top-line and bottom-line growth with a healthy dividend payout; long-term investors may continue to hold, though quarterly margin stagnation should be monitored.
Lincoln Pharma Q3 FY26 Net Profit Rises 37.7% to INR 28.6 Cr; Eyes INR 1,000 Cr Revenue Target
Lincoln Pharmaceuticals reported a strong Q3 FY26 with revenue growing 13.5% YoY to INR 166.32 crores and net profit jumping 37.7% to INR 28.60 crores. The management maintains a long-term revenue target of INR 1,000 crores, driven by the expansion of the Cepha block and entry into regulated markets. A new R&D center is expected to be operational within 2.5 months to support niche therapeutic product development. The company remains debt-free with significant cash reserves being deployed for potential inorganic growth opportunities.
Key Highlights
Net Profit increased by 37.7% YoY to INR 28.60 crores in Q3 FY26 compared to INR 20.77 crores in Q3 FY25.
Revenue from operations grew to INR 166.32 crores from INR 146.55 crores in the previous year.
Cepha block revenue is targeted to reach INR 90-100 crores next year, up from the current INR 45 crores.
EPS for the 9-month period reached INR 38.07, nearly matching the previous full year's EPS of INR 41.11.
Company is debt-free and exploring inorganic growth opportunities using substantial cash reserves yielding 10-12% returns.
👀 What to Watch
Investors should monitor the progress of the new R&D center and the ramp-up of the Cepha block as key drivers for the INR 1,000 crore revenue goal. The company's debt-free status and strong cash position provide a safety margin for long-term growth.
Lincoln Pharma Q3 Net Profit Surges 37.7% YoY to ₹28.6 Crore; Revenue Up 13.5%
Lincoln Pharmaceuticals reported a strong performance for the quarter ended December 31, 2025, with consolidated net profit rising 37.7% YoY to ₹28.60 crore. Revenue from operations grew by 13.5% YoY to ₹166.32 crore, supported by steady growth in its core pharmaceutical business. The company's profitability improved significantly on a sequential basis, with net profit jumping 43.1% compared to the previous quarter. For the nine-month period, the company maintained a healthy trajectory with a net profit of ₹76.26 crore on revenues of ₹483.75 crore.
Key Highlights
Consolidated Revenue from Operations grew 13.5% YoY to ₹166.32 crore in Q3 FY26
Net Profit for the quarter stood at ₹28.60 crore, up from ₹20.77 crore in the same period last year
Earnings Per Share (EPS) increased to ₹14.28 from ₹10.37 in Q3 FY25
Profit Before Tax (PBT) rose to ₹34.72 crore, reflecting improved operational efficiency
Nine-month (9M FY26) revenue reached ₹483.75 crore with a net profit of ₹76.26 crore
👀 What to Watch
The strong YoY and QoQ growth in profitability suggests robust operational performance. Investors should monitor the sustainability of these margins and the company's expansion in the pharmaceutical segment.
CRISIL Reaffirms Lincoln Pharmaceuticals' Credit Rating at 'CRISIL A/Stable' and 'CRISIL A1'
CRISIL has reaffirmed Lincoln Pharmaceuticals' long-term rating at 'CRISIL A/Stable' and short-term rating at 'CRISIL A1' for its Rs 102 crore bank facilities. The company maintains a robust financial profile with zero debt and a healthy net worth of Rs 671 crore as of March 31, 2025. Revenue grew by 14% YoY to Rs 623 crore in FY25, supported by a strong export presence contributing 60-65% of total sales. While the liquidity position is strong with Rs 173.1 crore in liquid investments, investors should monitor the increase in loans to affiliates, which rose to Rs 141 crore.
Key Highlights
CRISIL reaffirmed long-term rating at 'CRISIL A/Stable' and short-term rating at 'CRISIL A1' for Rs 102 crore facilities.
Company reported zero debt as of March 31, 2025, with a high interest coverage ratio of 91.01 times.
Revenue grew 14% year-on-year to Rs 623.23 crore in FY25, driven by 1,700 registered products.
Liquid investments in shares, debentures, and mutual funds stood at Rs 173.1 crore.
Loans and advances to affiliates increased to Rs 141 crore from Rs 104 crore in the previous year.
👀 What to Watch
The reaffirmation of ratings and zero-debt status highlights the company's strong solvency and financial health. Investors should remain positive but monitor the rising loans to affiliates and the working capital cycle.
